Barclays PLC Purchases 232,089 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Barclays PLC grew its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 402.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 289,688 shares of the company's stock after acquiring an additional 232,089 shares during the period. Barclays PLC owned 0.54% of Zevra Therapeutics worth $2,416,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. raised its position in Zevra Therapeutics by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company's stock valued at $23,554,000 after purchasing an additional 68,151 shares during the last quarter. Geode Capital Management LLC lifted its position in Zevra Therapeutics by 13.8% during the 4th quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company's stock worth $9,912,000 after buying an additional 144,256 shares in the last quarter. AIGH Capital Management LLC acquired a new position in Zevra Therapeutics during the 4th quarter worth about $6,577,000. Retirement Planning Co of New England Inc. grew its holdings in Zevra Therapeutics by 3.1% during the 4th quarter. Retirement Planning Co of New England Inc. now owns 514,832 shares of the company's stock worth $4,294,000 after acquiring an additional 15,327 shares during the last quarter. Finally, Mystic Asset Management Inc. raised its stake in shares of Zevra Therapeutics by 1.9% in the fourth quarter. Mystic Asset Management Inc. now owns 313,347 shares of the company's stock worth $2,613,000 after acquiring an additional 5,900 shares during the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Down 7.5 %

Shares of Zevra Therapeutics stock traded down $0.60 during trading on Tuesday, reaching $7.40. The stock had a trading volume of 424,427 shares, compared to its average volume of 617,732. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $404.62 million, a price-to-earnings ratio of -3.76 and a beta of 1.87. The stock has a fifty day moving average price of $7.51 and a two-hundred day moving average price of $8.08. Zevra Therapeutics, Inc. has a 52 week low of $4.20 and a 52 week high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. Sell-side analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ZVRA. Canaccord Genuity Group boosted their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. JMP Securities set a $18.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Guggenheim upped their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Thursday, March 13th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $22.29.

Insider Buying and Selling

In other news, CFO R. Laduane Clifton sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the sale, the chief financial officer now directly owns 51,361 shares of the company's stock, valued at $403,697.46. This trade represents a 17.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director John B. Bode purchased 10,000 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The stock was acquired at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the purchase, the director now owns 40,000 shares in the company, valued at $318,400. This trade represents a 33.33 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 85,773 shares of company stock worth $674,176. Corporate insiders own 2.40% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.